OncoMed files for $115m IPO to advance Phase II clinical trials
This article was originally published in Scrip
Redwood City, California-based OncoMed Pharmaceuticals filed for a $115 million initial public offering on 11 May, even though the oncology-focused company has more than a year's worth of cash on its balance sheet, to raise capital for three Phase II clinical trials.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.